Jose Cevallos Yepez, MD
Internal Medicine · Cape Coral, FLNPI 1922236736
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,077 of the $1,292 with a category attached, or 83.4%. 15 manufacturers reported payments, led by Ferring Pharmaceuticals AS at 39.9% of the total. Reporting peaked in 2019 at $579 and has fallen 81.0% since, to $110 in 2024.
Across 52 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals AS$515
- Johnson & Johnson$135
- AbbVie$129
- Novo Nordisk$77
- Novartis$72
- Boehringer Ingelheim$60
- plus $303 from 9 others
Across 1,139 payments — averaging $3736.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$924K
- Eli Lilly$822K
- Avanir Pharmaceuticals, Inc.$790K
- Novartis$421K
- Pfizer$357K
- Novo Nordisk AS$350K
- plus $592K from 7 others
What the payments were for
- Travel & lodging$21517%
- Food & beverage$1,07783%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals AS | 9 | $515 |
| Johnson & Johnson | 9 | $135 |
| AbbVie(2 entities) | 6 | $129 |
| Novo Nordisk | 5 | $77 |
| Novartis | 1 | $72 |
| Boehringer Ingelheim | 4 | $60 |
| GSK | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| AstraZeneca | 2 | $32 |
| Genentech, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOCDURNA$319
How this compares
$1,292 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $20,832 |
| Rosuvastatin Calcium | 37 | $490 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $317 |
| Atorvastatin Calcium | 39 | $304 |
| Omeprazole | 25 | $212 |
| Gabapentin | 14 | $201 |
| Amlodipine Besylate | 31 | $201 |
| Levothyroxine Sodium | 21 | $166 |
| Tamsulosin Hcl | 12 | $162 |
| Carvedilol | 15 | $158 |
| Losartan Potassium | 18 | $158 |
| Metformin Hcl | 34 | $141 |
| Donepezil Hcl | 17 | $136 |
| Pantoprazole Sodium | 21 | $108 |
| Glipizide | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $60 | $20,83212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Cape Coral
- Richard TorricelliCape Coral$65K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.